--
Alnylam
Pharmaceuticals ALNY announced today that it has presented new pre-clinical data
from two RNAi therapeutic programs for cardiovascular disease,
including: ALN-PCSsc, an RNAi therapeutic targeting PCSK9 for the
treatment of hypercholesterolemia; and ALN-ANG, an RNAi therapeutic
targeting ANGPTL3 for the treatment of genetic forms of mixed
hyperlipidemia and severe hypertriglyceridemia. These data were
presented at the American Heart Association (AHA) Scientific Sessions
held November 16 – 20, 2013 in Dallas, Texas. In a presentation titled “A
Subcutaneous Platform for RNAi Therapeutics Targeting Metabolic
Diseases: PCSK9 and ANGPTL3,” Alnylam scientists and
collaborators presented updated non-human primate (NHP) data showing
that subcutaneous administration of
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in